Skip to main content

NEUROTOXICIDAD INDUCIDA POR QUIMIOTERAPIA Y ESTADO NUTRICIONAL: BIOMARCADORES CLINICOS, SERICOS, RADIOLOGICOS Y NEUROFISIOLOGICOS ASOCIADOS AL DESARROLLO Y LA REGENERACION NERVIOSA.

PI20/00283

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION IDIBELL
Execution centre INSTITUTO DE INVESTIGACION BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma neurofilament light chain levels in chemotherapy-induced peripheral neurotoxicity according to type of anticancer drug

  • Velasco, Roser|||0000-0003-3194-9406
  • Marco, Carla
  • Domingo-Domenech, Eva|||0000-0001-8907-090X
  • Stradella, Agostina|||0000-0002-2307-8869
  • Santos Vivas, Cristina|||0000-0002-9854-5097
  • Laquente, Berta|||0000-0002-2477-1673
  • Ferrer, German
  • Argyriou, Andreas A.|||0000-0003-2131-7114
  • Bruna, Jordi|||0000-0001-6895-5047
A real-time biomarker in chemotherapy-induced peripheral neurotoxicity (CIPN) would be useful for clinical decision-making during treatment. Neurofilament light chain (NfL) can be detected in blood in the case of neuroaxonal damage. The aim of the study was to compare the levels of plasma NfL (pNfL) according to the type of chemotherapeutic agent and the severity of CIPN. This single-center prospective observational longitudinal study included patients treated with paclitaxel (TX; n = 34), brentuximab vedotin (BV; n = 29), or oxaliplatin (PT; n = 19). All patients were assessed using the Total Neuropathy Score-clinical version and Common Terminology Criteria for Adverse Events before, during, and up to 6-12 months after the end of treatment. Nerve conduction studies (NCS) were performed before and after chemotherapy discontinuation. Consecutive plasma samples were analyzed for NfL levels using a Simoa ® analyzer. Changes in pNfL were compared between groups and were eventually correlated with clinical and NCS data. Clinically relevant (CR) CIPN was considered to be grade ≥ 2. Eighty-two patients, mostly women (59.8%), were included. One third of the patients who received TX (29.4%), BV (31%), or PT (36.8%) developed CR-CIPN, respectively, without differences among them (p = 0.854). Although pNfL significantly increased during treatment and decreased throughout the recovery period in all three groups, patients receiving TX showed significantly greater and earlier changes in pNfL levels compared to the other agents (p < 0.001). A variable change in pNfL is observed depending on the type of agent and mechanism of neurotoxicity with comparable CIPN severity, strongly implying the need to identify different cutoff values for each agent.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Brentuximab-Induced Peripheral Neurotoxicity, A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy

  • Velasco, Roser|||0000-0003-3194-9406
  • Domingo-Domenech, Eva|||0000-0001-8907-090X
  • Sureda, Anna|||0000-0002-1238-6970
This article highlights the importance of monitoring peripheral neurotoxicity in patients with Hodgkin lymphoma (HL) who receive brentuximab vedotin, with a particular focus on early recognition and multidisciplinary management of this type of toxicity. Brentuximab vedotin-induced neurotoxicity (BVIN) is the most common non-haematological complication and cause of dose-delay or early discontinuation of BV treatment. An accurate and prompt diagnosis in patients with HL is essential to optimise management of this potentially disabling complication. Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate approved to treat classical Hodgkin lymphoma (HL). BV-induced peripheral neurotoxicity (BVIN) is one of the greatest concerns for haematologists treating HL for several reasons. First, BVIN is highly frequent. Most patients receiving BV will experience some degree of BVIN, resulting in the primary reason for dose modification or discontinuation of HL therapy. Second, BV produces sensory, motor, and/or autonomic peripheral nerve dysfunction, which can present as severe, disabling forms of BVIN-predominantly motor-in some patients. Third, although largely reversible, BVIN may persist months or years after treatment and thereby become a major issue in HL survivorship. BVIN may, therefore, negatively affect the quality of life and work-life of often young patients with HL, in whom long-term survival is expected. Currently, the only strategy for BVIN includes dose adjustments and treatment discontinuation; however, this could interfere with LH therapy efficacy. In this setting, early recognition and adequate management of BVIN are critical in improving clinical outcomes. Careful neurologic monitoring may allow accurate diagnoses and gradation of ongoing forms of BVIN presentation. This review analysed current, available data on epidemiology, pathophysiology, patient- and treatment-related risk factors, clinical and neurophysiologic phenotypes, and management in patients with HL. Furthermore, this review specifically addresses limitations posed by BVIN assessments in clinical practice and provides skills and tools to improve neurologic assessments in these patients. Integrating this neurotoxic drug in clinical practice requires a multidisciplinary approach to avoid or minimise neurotoxicity burden in survivors of HL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

  • Velasco, Roser|||0000-0003-3194-9406
  • Alemany Martí, Montserrat|||0000-0002-7039-4186
  • Villagrán, Macarena|||0000-0001-9236-2428
  • Argyriou, Andreas A.|||0000-0003-2131-7114
Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OXA infusion, and chronic non-length dependent sensory neuronopathy symmetrically affecting both upper and lower limbs in a stocking-and-glove distribution. No effective strategy has been established to reverse or treat OXAIPN. Thus, it is necessary to early predict the occurrence of OXAIPN during treatment and possibly modify the OXA-based regimen in patients at high risk as an early diagnosis and intervention may slow down neuropathy progression. However, identifying which patients are more likely to develop OXAIPN is clinically challenging. Several objective and measurable early biomarkers for OXAIPN prediction have been described in recent years, becoming useful for informing clinical decisions about treatment. The purpose of this review is to critically review data on currently available or promising predictors of OXAIPN. Neurological monitoring, according to predictive factors for increased risk of OXAIPN, would allow clinicians to personalize treatment, by monitoring at-risk patients more closely and guide clinicians towards better counseling of patients about neurotoxicity effects of OXA.